AbbVie Inc. $ABBV Stock Sold by State of Alaska Department of Revenue

State of Alaska Department of Revenue lowered its stake in shares of AbbVie Inc. (NYSE:ABBV) by 2.5% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 226,864 shares of the company’s stock after selling 5,719 shares during the period. AbbVie makes up approximately 0.6% of State of Alaska Department of Revenue’s portfolio, making the stock its 27th biggest holding. State of Alaska Department of Revenue’s holdings in AbbVie were worth $59,344,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. Charles Schwab Trust Co grew its stake in shares of AbbVie by 1.8% in the 3rd quarter. Charles Schwab Trust Co now owns 32,249 shares of the company’s stock worth $8,436,000 after acquiring an additional 557 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors lifted its position in shares of AbbVie by 4.0% during the third quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors now owns 21,084 shares of the company’s stock valued at $5,516,000 after purchasing an additional 803 shares in the last quarter. Kellett Wealth Advisors LLC lifted its position in shares of AbbVie by 1.8% during the third quarter. Kellett Wealth Advisors LLC now owns 3,485 shares of the company’s stock valued at $912,000 after purchasing an additional 61 shares in the last quarter. Colorado Capital Management Inc. purchased a new position in AbbVie during the third quarter worth about $206,000. Finally, KG Capital Management purchased a new position in AbbVie during the third quarter worth about $258,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Down 0.1%

ABBV opened at $283.07 on Friday. AbbVie Inc. has a twelve month low of $190.75 and a twelve month high of $291.40. The company’s 50-day moving average price is $261.95 and its two-hundred day moving average price is $238.90. The stock has a market cap of $500.13 billion, a price-to-earnings ratio of 79.96, a PEG ratio of 1.29 and a beta of 0.24.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. AbbVie’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter last year, the business posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, sell-side analysts anticipate that AbbVie Inc. will post 13.94 earnings per share for the current year.

AbbVie Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s dividend payout ratio is 195.48%.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ABBV. HSBC upped their price objective on shares of AbbVie from $300.00 to $315.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. JPMorgan Chase & Co. lifted their target price on shares of AbbVie from $285.00 to $300.00 and gave the stock an “overweight” rating in a research report on Thursday, October 8th. Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 5th. Scotiabank boosted their target price on AbbVie from $280.00 to $320.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 6th. Finally, Wolfe Research raised AbbVie from a “peer perform” rating to an “outperform” rating and upped their target price for the company from $235.00 to $300.00 in a report on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $277.18.

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.06% of the stock is owned by corporate insiders.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: New Phase 3 data for a subcutaneous version of SKYRIZI showed meaningful clinical and endoscopic benefits in adults with moderately to severely active Crohn’s disease. The results could support regulatory review of a more convenient induction option and strengthen confidence that SKYRIZI can help offset the loss of Humira revenue. Abbvie’s Crohn’s Disease Drug Skyrizi Shows More Positive Results
• Positive Sentiment: Analyst sentiment remains constructive. Royal Bank of Canada reaffirmed an Outperform rating, while Erste Group raised its 2027 EPS estimate to $16.34 from $16.19 and maintained a Buy rating. These views reinforce the argument that AbbVie’s newer drugs are driving sustainable post-Humira growth. Royal Bank Of Canada Reaffirms Outperform Rating for AbbVie
• Positive Sentiment: Investors are also watching early clinical work on oral candidate ABBV-1042. The study remains at an early stage and is being conducted in healthy participants, but positive progress could add value to AbbVie’s long-term pipeline. AbbVie’s ABBV-1042 Trial Update
• Neutral Sentiment: AbbVie’s third-quarter earnings report is scheduled for October 30. Investors will be looking for confirmation that SKYRIZI and RINVOQ growth is more than compensating for Humira’s decline; the company’s current guidance calls for third-quarter EPS of $3.84 to $3.88. AbbVie’s Q3 2026 Earnings: What to Expect
• Neutral Sentiment: Heavy call-option activity and a broad healthcare-sector rally indicate increased investor interest, but options positioning is not a fundamental catalyst by itself. Lower Treasury yields may also be supporting defensive healthcare shares.
• Negative Sentiment: Some investors remain concerned that AbbVie’s valuation is demanding after its rally. Comparisons with Sanofi have highlighted Sanofi’s stronger outlook and valuation, potentially limiting further upside. Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?

AbbVie Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.